Management of Patients After Acute Coronary Syndrome Rule-Out

Dual Antiplatelet Therapy

The European Society of Cardiology recommends dual antiplatelet therapy with a P2Y12 inhibitor, such as ticagrelor 90mg twice daily, for all patients after ACS rule-out, even with an ischemia-guided strategy 3
Ticagrelor 90mg twice daily is preferred over clopidogrel based on mortality benefit in contemporary guidelines from the European Heart Journal 1, 2
If ticagrelor is not tolerated or contraindicated, clopidogrel 75mg daily is an acceptable alternative, as recommended by the American Heart Association 3
Dual antiplatelet therapy should continue for up to 12 months in all patients with NSTE-ACS without contraindications, according to the American College of Cardiology 3

The American Heart Association recommends continuing the current aspirin dose of 81mg daily indefinitely, as it is appropriate for patients after ACS rule-out 5, 6, 3
When used with ticagrelor, the maintenance dose must be 81mg daily, as higher doses increase bleeding without improving efficacy, according to the European Heart Journal 3
Lower aspirin doses (75-162mg) have similar efficacy to higher doses but significantly less bleeding risk, with major bleeding rates of 2.0% with <100mg versus 4.0% with >200mg daily, as reported in the Circulation journal 5, 6

The European Society of Cardiology recommends metoprolol 12.5mg BID as a reasonable starting dose, but requires upward titration, as stated in the European Heart Journal 4
With a normal EF of 65%, beta-blockers are not mandated by guidelines, but remain beneficial for symptom control and are reasonable to continue, titrating to target heart rate of 50-60 bpm as tolerated, according to the American College of Cardiology 1, 2, 8
Avoid beta-blockers if there are signs of coronary vasospasm or recent cocaine use, as recommended by the American Heart Association 8

The European Society of Cardiology recommends rosuvastatin 20mg daily, which represents high-intensity statin therapy and is appropriate for patients after ACS rule-out, as stated in the European Heart Journal 1, 2, 7
Target LDL-C reduction of ≥50% from baseline and achieve LDL-C <55 mg/dL (<1.4 mmol/L), as recommended by the American College of Cardiology 7
Continue statin therapy indefinitely as a Class I recommendation, according to the European Heart Journal 1, 2

The European Society of Cardiology recommends an ACE inhibitor if the patient has LVEF ≤40%, heart failure, hypertension, or diabetes, as stated in the European Heart Journal 1, 2, 7
With EF 65%, ACE inhibitor is only indicated if comorbid hypertension or diabetes is present, according to the American College of Cardiology 1, 2
If ACE inhibitor is indicated but not tolerated, use an ARB as alternative, as recommended by the American Heart Association 1, 2

The European Society of Cardiology recommends adding a proton pump inhibitor if the patient is at high risk for gastrointestinal bleeding, as stated in the European Heart Journal 7
Lifestyle modifications are Class I recommendations, including smoking cessation, regular physical activity (≥30 minutes, ≥3 times weekly), and healthy diet, according to the American College of Cardiology 1, 2
Enroll in cardiac rehabilitation program to enhance compliance and promote lifestyle changes, as recommended by the American Heart Association 2
Blood pressure target: diastolic <90 mmHg (<85 mmHg if diabetic), according to the European Heart Journal 1

The American College of Cardiology recommends not discharging ACS patients on aspirin monotherapy, as this is the most critical error in this case, as stated in the Circulation journal 3
Do not use aspirin doses >81mg when combining with ticagrelor, as this increases bleeding without improving efficacy, according to the American Heart Association 3
Do not assume beta-blockers are mandatory with normal EF—they are beneficial but not Class I indicated, as recommended by the European Society of Cardiology 1, 2